NetraMark Holdings (XCNQ:AIAI) ROE % Adjusted to Book Value : -6.92% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings ROE % Adjusted to Book Value?

NetraMark Holdings's ROE % for the quarter that ended in Mar. 2024 was -691.79%. NetraMark Holdings's PB Ratio for the quarter that ended in Mar. 2024 was 100.00. NetraMark Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -6.92%.

NetraMark Holdings ROE % Adjusted to Book Value Historical Data

The historical data trend for NetraMark Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings ROE % Adjusted to Book Value Chart

NetraMark Holdings Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

ROE % Adjusted to Book Value

-14.64

-106.70

-13.61

NetraMark Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial										-104.07	-27.27	-	-10.38	-6.92

Competitive Comparison of NetraMark Holdings's ROE % Adjusted to Book Value

For the Health Information Services subindustry, NetraMark Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NetraMark Holdings's ROE % Adjusted to Book Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NetraMark Holdings's ROE % Adjusted to Book Value falls into.

NetraMark Holdings ROE % Adjusted to Book Value Calculation

NetraMark Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-308.16%	/	22.65
	=	-13.61%

NetraMark Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-691.79%	/	100.00
	=	-6.92%

NetraMark Holdings ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NetraMark Holdings (XCNQ:AIAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

AINMF:USA

Address

1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1

Website

https://www.nurosene.com

NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.

Executives

Andrew Parks

Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines